Compounded vs. Brand-Name GLP-1 Medicines: What Changes?
Understand FDA approval, compounding, pharmacy checks, and the questions to ask when comparing compounded and brand-name GLP-1 medicines.
On this page
The short answer
Compounded GLP-1 preparations are not FDA-approved and are not approved generic versions of brand-name medicines. They may serve a specific medical need, but you should understand why one is being recommended, which pharmacy prepares it, and how its instructions differ from a branded product.
The distinction is about the finished medicine
Compounding means preparing a medicine for particular patient needs. It can be useful when an approved product is medically unsuitable, but compounded preparations do not undergo FDA’s approval process. Pharmacy oversight and product approval answer different questions. 1
When comparing offers, ask about the finished preparation you would receive, not only the ingredient name. An ingredient name cannot tell you who made the medicine, its concentration, or whether the product has FDA approval.
If you are still getting familiar with the terminology, our GLP-1 guide explains how ingredient, product, and formulation fit together.
Compounded is not the same as generic
| Category | What it means |
|---|---|
| FDA-approved brand-name medicine | A specific product that has completed FDA review |
| FDA-approved generic | A product that must meet FDA requirements, including equivalence to its reference drug |
| Compounded preparation | A preparation made under the applicable compounding framework, without FDA approval as a finished drug |
An approved generic must meet standards for factors including strength, dosage form, quality, and bioequivalence. A compounded preparation has not established approval through that pathway. Calling a preparation “generic Wegovy” does not change its status. 1 2
Likewise, “made in a licensed pharmacy” does not mean FDA has approved that pharmacy’s individual compounded products. 1
Ask why compounding is being recommended
FDA recommends compounded drugs only when an FDA-approved drug cannot meet a patient’s medical needs. Its current GLP-1 guidance also flags marketing that describes a compounded preparation as the same as an approved product. 3
A useful conversation starts with these questions:
- “What is the specific reason you recommend this preparation for me?”
- “Which approved alternatives have we considered?”
- “What are the uncertainties I should understand?”
- “Who will answer questions about the preparation after it arrives?”
Ask for an explanation that relates to your assessment. A general statement about what a company sells is not an explanation of why a particular prescription is appropriate for you.
If cost is the main concern, say so directly and ask to compare all available routes. Our GLP-1 cost guide can help organize the financial questions without treating price as evidence that two products are equivalent.
Verify the pharmacy separately from the website
Get the pharmacy’s legal name and contact information. Use FDA’s directory of state pharmacy boards to check licensing; confirm the pharmacy requires a prescription and provides access to a pharmacist. 5
Keep the details together with your prescription. A simple record can include:
| Information to keep | Why it is useful |
|---|---|
| Prescriber and care-team contact | You know who manages the clinical plan |
| Dispensing pharmacy and phone number | You know whom to ask about the supplied preparation |
| Medication label | You can read back the exact product and instructions |
| Order and delivery dates | You can explain the timeline if there is a problem |
| Written care and billing terms | You can check what was agreed before paying |
Take a clear photograph of the label when the medicine arrives. This makes it easier to discuss a concern without relying on memory. For broader care questions, see how to choose an online provider.
Why instructions need to match your exact supply
FDA has documented dosing errors with compounded injectable semaglutide, including confusion among milligrams, milliliters, and syringe units. Concentrations can differ. The agency advises counseling with the appropriate syringe and instructions for the intended dose. 4
Before using a new supply, ask the pharmacist to confirm the label, device, and written directions together. If any of them are inconsistent or unclear, resolve that first. Do not use a social-media diagram, a friend’s instructions, or the marks on an old syringe as a substitute.
Ask again when a preparation or device changes. “I have done this before” is not a reason to guess about unfamiliar instructions.
Storage and opened vials need specific answers
FDA’s current compounded GLP-1 guidance advises discarding multidose vials within 28 days of first use, even if a compounder gives a longer period. It also advises against using injectable GLP-1 medicine that arrives warm or without sufficient refrigeration. Contact the pharmacy or care team about a concerning delivery before using it. 3
Ask which date applies to an unopened supply and which applies once a vial has been opened. Put the opening date in your medication record. A package containing several months of treatment does not, by itself, answer how long each opened container can be used.
Read ingredient claims carefully
FDA distinguishes semaglutide sodium and semaglutide acetate from the active ingredient in approved semaglutide products. The agency says it lacks evidence that these salts have the same properties and is unaware of a lawful basis for their use in compounding. 3
The agency also notes that the safety and effectiveness of combining semaglutide with added ingredients, such as certain vitamins, have not been established. An extra ingredient should prompt a question about its purpose, not an assumption that the preparation works better. 4
Common questions
Can a brand-name study prove results for a compounded preparation?
A trial evaluates the products and treatment conditions actually studied. It does not establish that another finished preparation will produce the same results. Our semaglutide versus tirzepatide article identifies the study behind its comparison.
Is checking a pharmacy’s license enough?
It is one useful check. You still need to understand the prescription, the reason for using the preparation, instructions, and follow-up. Keep your questions about the provider and the pharmacy separate so each reaches the right person.
What should I do if the label does not match what I expected?
Set the medicine aside and contact the pharmacy and prescriber before using it. Ask them to explain the discrepancy using the label in front of you. If you have already taken an uncertain dose, seek prompt professional advice rather than trying to correct it yourself.
References
- Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration
- Generic Drug Facts — U.S. Food and Drug Administration
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — U.S. Food and Drug Administration
- FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products — U.S. Food and Drug Administration
- Locate a State-Licensed Online Pharmacy — U.S. Food and Drug Administration
For your information. This article provides general education and does not replace medical advice or an individual evaluation. Talk to your clinician before starting, changing, or stopping treatment. Compounded medications are not FDA-approved.